Concepedia

Author

Xue‐Ning Yang

Guangdong Academy of Medical SciencesORCID

Also Known As

Ming-fang Zhao, X N Yang, X. Yang, X., Yang, X.-N. Yang, X.N. Yang, Xue-Ning Yang, Xue-ning Yang, Xuening YANG, Xuening Yang

279

Publications

6.5K

Citations

36

H-Index

61

Concepts

All Affiliations

Guangdong Academy of Medical SciencesGuangdong General HospitalGuangdong Provincial People's HospitalSouthern Medical UniversitySouth China University of Technology
XY

About

Xue‐Ning Yang is an author at Guangdong Academy of Medical Sciences specializing in medicine, lung cancer, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

19

22

1.9K

2

Engineering

3

3

59

3

Public Health

3

3

108

4

Health Sciences

2

2

149

5

Biostatistics

2

2

56

Xue‐Ning Yang

×

64

Publications

5.6K

Citations

33

H-Index

YearCitations

Potential Predictive Value of <i>TP53</i> and <i>KRAS</i> Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

Zhong‐Yi Dong, Wen‐Zhao Zhong, Xu‐Chao Zhang,

Clinical Cancer Research

2016

971

Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study

Wen‐Zhao Zhong, Qun Wang, Weimin Mao,

The Lancet Oncology

2017

520

Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy

Y.S. Li, Bo Jiang, Jin‐Ji Yang,

Annals of Oncology

2018

328

Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression

Xu‐Chao Zhang, Shirley Zhang, Xue‐Ning Yang,

Molecular Cancer

2010

298

Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial

Wen‐Zhao Zhong, Qun Wang, Weimin Mao,

Journal of Clinical Oncology

2020

261

Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 <i>EGFR</i>-Mutant Non–Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study

Wen‐Zhao Zhong, Ke‐Neng Chen, Chun Chen,

Journal of Clinical Oncology

2019

259

Relative Abundance of <i>EGFR</i> Mutations Predicts Benefit From Gefitinib Treatment for Advanced Non–Small-Cell Lung Cancer

Qing Zhou, Xu‐Chao Zhang, Zhihong Chen,

Journal of Clinical Oncology

2011

241

Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non–Small Cell Lung Cancer

Jia‐Tao Zhang, Si‐Yang Liu, Wei Gao,

Cancer Discovery

2022

211

A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations

Jin‐Ji Yang, Qing Zhou, Hong‐Hong Yan,

British Journal of Cancer

2017

172

Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer

Jin‐Ji Yang, Hua‐Jun Chen, Hong‐Hong Yan,

Lung Cancer

2012

164

Page 1